Patents by Inventor Yen-Lun Huang

Yen-Lun Huang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for the treatment of angiogenesis-related eye diseases
    Patent number: 9044436
    Abstract: The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine.
    Type: Grant
    Filed: December 22, 2010
    Date of Patent: June 2, 2015
    Assignees: National Cheng Kung University, National Taiwan University
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Yen-Lun Huang
  • Methods of treating ?v?3 integrin-associated diseases by administering polypeptides selective for ?v?3 integrin
    Patent number: 8183201
    Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: May 22, 2012
    Assignees: National Cheng Kung University, National Taiwan University
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Mannching Sherry Ku, Yen-Lun Huang
  • Polypeptides Selective for avB3 Integrin, Including Pegylated Polypeptides, And Pharmaceutical Uses Thereof
    Publication number: 20110166072
    Abstract: The invention provides disintegrin variants, and more specifically to disintegrin variants which are selective ?v?3 integrin antagonists for treatment and prevention of ?v?3 integrin-associated diseases. The present invention also relates to pegylated proteins, including proteins comprising a disintegrin variant having an RGD motif variant 48ARLDDL53. The invention also relates to the use of the polypeptides of the invention for the treatment and prevention of ?v?3 integrin-associated diseases.
    Type: Application
    Filed: February 25, 2011
    Publication date: July 7, 2011
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Mannching Sherry Ku, Yen-Lun Huang
  • Compositions and Methods for the Treatment of Angiogenesis-Related Eye Diseases
    Publication number: 20110152192
    Abstract: The invention generally relates to compositions and methods of treatment and/or prevention of angiogenesis-related eye diseases using low doses of rhodostomin variants, and in particular, low doses of a fusion protein comprising a rhodostomin variant, wherein the rhodostomin variant is conjugated with a variant of Human Serum Albumin (HSA) where the cysteine residue at position 34 of the HSA amino acid sequence has been replaced with serine.
    Type: Application
    Filed: December 22, 2010
    Publication date: June 23, 2011
    Inventors: Woei-Jer Chuang, Wen-Mei Fu, Yen-Lun Huang
  • METHODS FOR DIAGNOSING DIABETES AND DETERMINING EFFECTIVENESS OF TREATMENTS
    Publication number: 20110045522
    Abstract: The invention generally relates to novel methods of measuring the effectiveness of a drug for the treatment of diabetes and methods of diagnosing diabetes. In some embodiments of the invention, IL-1Ra is used as a biomarker to measure the effectiveness of a drug for the treatment of diabetes.
    Type: Application
    Filed: August 20, 2010
    Publication date: February 24, 2011
    Inventors: Danchen Gao, Yen-Lun Huang, Feng-Min Lin, Wei-Shu Lu